950 Lee's Pharmaceutical Holdings Limited
Lee's Pharmaceutical Holdings (950) news
Lee's Pharmaceutical Holdings Limited is a public biotech or pharmaceutical company listed on HKEX under the ticker 950, recorded under Hong Kong. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Latest Lee's Pharmaceutical Holdings news
We have not published a story on Lee's Pharmaceutical Holdings yet. When there is news, it will appear here.
Questions about Lee's Pharmaceutical Holdings
What is the ticker symbol of Lee's Pharmaceutical Holdings?
Lee's Pharmaceutical Holdings Limited trades under the ticker 950 on HKEX.
Where is Lee's Pharmaceutical Holdings listed?
Lee's Pharmaceutical Holdings Limited is listed on HKEX.
Which country or territory is Lee's Pharmaceutical Holdings listed under?
Our directory records Lee's Pharmaceutical Holdings Limited under Hong Kong.
What does Lee's Pharmaceutical Holdings do?
Our directory classifies Lee's Pharmaceutical Holdings Limited as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Lee's Pharmaceutical Holdings?
The ISIN recorded for Lee's Pharmaceutical Holdings Limited is KYG5438W1116.
Does aibio.space cover Lee's Pharmaceutical Holdings?
aibio.space lists Lee's Pharmaceutical Holdings Limited among 2,820 public biotech companies and publishes its news here as stories appear.
Which companies are similar to Lee's Pharmaceutical Holdings?
Companies in our directory listed in the same country and business area as Lee's Pharmaceutical Holdings: Shenzhen Neptunus Interlong Bio-Technique Co., Beijing Tong Ren Tang Chinese Medicine Co., Regent Pacific Group, Extrawell Pharmaceutical Holdings, China Biotech Services Holdings, Pak Fah Yeow International.
Investor discussion: Lee's Pharmaceutical Holdings
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Financings
Share or debt issue: General Mandates to Repurchase Shares and to Issue New Shares, Re-election of Directors and Notice of Annual General Meeting. Source
- Mergers
Transaction under the Listing Rules: Supplemental Announcement in Relation to Discloseable Transaction - Acquisition of Assets. Source
- Mergers
Transaction under the Listing Rules: Discloseable Transaction - Acquisition of Assets. Source
- Financings
Share or debt issue: General Mandates to Repurchase Shares and to Issue New Shares, Re-election of Directors and Notice of Annual General Meeting. Source
Press releases
- HKEXnews
- HKEXnews
- HKEXnews
- HKEXnews
- HKEXnews
- HKEXnews
- HKEXnews
- HKEXnews
- HKEXnews
Voluntary Announcement - Share Repurchase Program under the Repurchase Mandate
- HKEXnews
Voluntary Announcement - Funding Approved for Synthetic Surfactant Project
- HKEXnews
- HKEXnews
- HKEXnews
Notification Letter to Non-registered Shareholders and Reply Form
- HKEXnews
Notification Letter to Registered Shareholders and Reply Form
- HKEXnews
- HKEXnews
- HKEXnews
- HKEXnews
Announcement of Annual Results for the Year Ended 31 December 2025
- HKEXnews
- HKEXnews
Voluntary Announcement - FDA Approval of Supplemental New Drug Application for Adasuve
Stock chart
Listing details
- Company
- Lee's Pharmaceutical Holdings Limited
- Ticker
- 950
- Listing
- HKEX
- Country or territory
- Hong Kong
- Business scope
- Pharmaceuticals: Major
- ISIN
- KYG5438W1116
- Last quote in directory
- 2026-10-22
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio